Variant-proof vaccines — invest now for the next pandemic
- 8 February 2021
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Nature
- Vol. 590 (7846), 386-388
- https://doi.org/10.1038/d41586-021-00340-4
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibodyScience, 2021
- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7Published by Cold Spring Harbor Laboratory ,2021
- The impact of Spike mutations on SARS-CoV-2 neutralizationPublished by Cold Spring Harbor Laboratory ,2021
- Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike proteinPublished by Cold Spring Harbor Laboratory ,2020
- Broad neutralization of SARS-related viruses by human monoclonal antibodiesScience, 2020
- Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibodyNature, 2020
- Structural basis of broad ebolavirus neutralization by a human survivor antibodyNature Structural & Molecular Biology, 2019
- Recent progress in broadly neutralizing antibodies to HIVNature Immunology, 2018
- Broadly Neutralizing Antiviral AntibodiesAnnual Review of Immunology, 2013